Rectal Cancer – organ preserving treatment (extension to CR29)

Gender Neutral
Type Module
Testing Phase II / II - in development
Principal investigator(s)
Alexandra Gilbert
University of Leeds
Leeds, United Kingdom
Study coordinator(s)
Carole Paley
Leeds Institute for Medical Research
Leeds, United Kingdom

Project summary

The EORTC colorectal module (QLQ-CR29) is the most commonly used patient reported outcome measure in colorectal cancer clinical trials. The results of the updated colorectal module validation were published in 2009. However, since then the treatment landscape has changed for example, with the introduction of molecular targeted treatments and organ preservation approaches to treatment. The aim of this project is to update the QLQ-CR29 and provide an opportunity to amend the wording on relevant items and to add or remove items as relevant.

Achievements

Research fellow in post 1st September 2025

Current status:

Scoping review and ethics application under way

Future plans

Health care and patient interviews to start Q1-2 2026

For patients

To update the EORTC QLQ-CR29 (which was last updated in 2009), to ensure our questionnaire covers the quality of life issues for current treatments for patients with colorectal cancer.

Go to Top